John is a trailblazing entrepreneur with a remarkable track record of success in genomics, proteomics, and AI-driven therapeutics. Recognized in 2013 as one of the top 15 Technology Luminaries in Massachusetts by the Boston Business Journal and Mass High Technology, John has consistently demonstrated an unparalleled ability to build and position companies for acquisition or IPO.
With over $800MM in funding raised from venture capital, strategic partnerships, and private investors, John has driven more than $1.8 billion in exits, delivering substantial returns with exceptional speed. His ability to integrate cutting-edge technology, including AI, into life sciences has positioned him as a leader at the intersection of innovation and entrepreneurship.
As the co-founder of Tiger Gene, funded by Tiger Management, John continues to harness the transformative power of AI to advance genomics and proteomics solutions. Prior to this, John served as President and CEO of Exosome Diagnostics, a liquid biopsy company that he revitalized and led to a $575MM acquisition by Bio-Techne in just 2.5 years. Upon joining the company in 2015 during a critical financial period, John implemented his visionary "3 Pillar Strategy," established a Companion Diagnostics division, and brought in Tiger Management to secure a $60MM Series B round. He subsequently raised an oversubscribed $33MM Series C round, driving Exosome to a 6X return for investors.
Beyond the boardroom, John is a passionate educator and innovation advocate. A Fellow at Harvard University since 2014, he teaches the acclaimed course "Entrepreneurship and Innovation" (ES-139). Under his guidance, the class expanded from 8 students to over 420, becoming one of Harvard's most attended courses, taught in the iconic Sanders Theater.
John’s visionary leadership, ability to integrate AI into cutting-edge industries, and dedication to fostering innovation make him a cornerstone of our AI program’s mission to revolutionize entrepreneurship and technology.
